AIM IMMUNOTECH INC. (AIM) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
24/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseAIM / S&P -52.54% / 15.20% |
LoseAIM / S&P -21.49% / 15.00% |
LoseAIM / S&P -100.05% / 50.40% |
| 2026-Q10/3 |
LoseAIM / S&P -46.17% / -4.33% |
LoseAIM / S&P -35.62% / 11.30% |
LoseAIM / S&P -82.92% / 27.70% |
| 2025-Q40/3 |
LoseAIM / S&P -58.76% / 2.65% |
LoseAIM / S&P -48.24% / 9.00% |
LoseAIM / S&P -86.34% / 13.40% |
| 2025-Q31/3 |
LoseAIM / S&P -68.32% / 8.12% |
LoseAIM / S&P -41.05% / 4.61% |
WinAIM / S&P 28.78% / 13.45% |
| 2025-Q21/3 |
LoseAIM / S&P -27.92% / 10.94% |
LoseAIM / S&P -39.80% / 4.83% |
WinAIM / S&P 455.08% / 10.63% |
| 2025-Q11/3 |
LoseAIM / S&P -40.00% / -4.27% |
LoseAIM / S&P -24.35% / 4.98% |
WinAIM / S&P 2864.06% / 10.57% |
| 2024-Q41/3 |
LoseAIM / S&P -25.93% / 2.41% |
LoseAIM / S&P -15.84% / 5.25% |
WinAIM / S&P 3073.33% / 6.15% |
| 2024-Q31/3 |
LoseAIM / S&P -27.03% / 5.89% |
LoseAIM / S&P -1.55% / 5.89% |
WinAIM / S&P 2081.40% / 6.11% |
| 2024-Q22/3 |
LoseAIM / S&P -21.28% / 4.28% |
WinAIM / S&P 19.64% / 5.38% |
WinAIM / S&P 785.00% / 5.12% |
| 2024-Q12/3 |
LoseAIM / S&P 6.82% / 10.56% |
WinAIM / S&P 23.72% / 5.71% |
WinAIM / S&P 60.00% / 5.59% |
| 2023-Q41/3 |
LoseAIM / S&P -4.35% / 11.69% |
WinAIM / S&P 44.29% / 6.81% |
LoseAIM / S&P AIM unavailable / 7.78% |
| 2023-Q31/3 |
LoseAIM / S&P -31.34% / -3.27% |
WinAIM / S&P 44.03% / 7.52% |
LoseAIM / S&P AIM unavailable / -5.03% |
| 2023-Q22/3 |
WinAIM / S&P 55.81% / 8.74% |
WinAIM / S&P 15.07% / 9.50% |
LoseAIM / S&P AIM unavailable / -8.57% |
| 2023-Q12/3 |
WinAIM / S&P 38.71% / 7.50% |
WinAIM / S&P 12.23% / 10.77% |
LoseAIM / S&P AIM unavailable / -15.69% |
| 2022-Q40/3 |
LoseAIM / S&P -46.55% / 7.56% |
LoseAIM / S&P 4.48% / 11.88% |
LoseAIM / S&P AIM unavailable / -17.99% |
| 2022-Q30/3 |
LoseAIM / S&P -25.64% / -4.88% |
LoseAIM / S&P 6.35% / 13.47% |
LoseAIM / S&P AIM unavailable / -1.41% |
| 2022-Q20/3 |
LoseAIM / S&P -26.42% / -16.10% |
LoseAIM / S&P 13.18% / 13.71% |
LoseAIM / S&P AIM unavailable / 11.04% |
| 2022-Q11/3 |
WinAIM / S&P 15.22% / -4.60% |
LoseAIM / S&P -4.79% / 15.97% |
LoseAIM / S&P AIM unavailable / 42.23% |
| 2021-Q40/3 |
LoseAIM / S&P -54.46% / 11.03% |
LoseAIM / S&P -17.79% / 15.00% |
LoseAIM / S&P AIM unavailable / 96.40% |
| 2021-Q30/3 |
LoseAIM / S&P -6.05% / 0.58% |
LoseAIM / S&P -26.32% / 10.77% |
LoseAIM / S&P AIM unavailable / 69.42% |
| 2021-Q20/3 |
LoseAIM / S&P -5.29% / 8.55% |
LoseAIM / S&P -34.18% / 6.58% |
LoseAIM / S&P AIM unavailable / 51.81% |
| 2021-Q11/3 |
WinAIM / S&P 26.82% / 6.17% |
LoseAIM / S&P -21.08% / -1.06% |
LoseAIM / S&P AIM unavailable / 7.39% |
| 2020-Q40/3 |
LoseAIM / S&P -16.74% / 12.15% |
LoseAIM / S&P AIM unavailable / -3.72% |
LoseAIM / S&P AIM unavailable / -33.42% |
| 2020-Q30/3 |
LoseAIM / S&P -13.31% / 8.93% |
LoseAIM / S&P AIM unavailable / -2.04% |
LoseAIM / S&P AIM unavailable / -27.10% |
| 2020-Q20/3 |
LoseAIM / S&P -3.12% / 20.54% |
LoseAIM / S&P AIM unavailable / -0.46% |
LoseAIM / S&P AIM unavailable / -27.11% |
| 2020-Q11/3 |
WinAIM / S&P 374.07% / -19.60% |
LoseAIM / S&P AIM unavailable / 3.47% |
LoseAIM / S&P AIM unavailable / -14.75% |
| 2019-Q40/3 |
LoseAIM / S&P -28.95% / 9.07% |
LoseAIM / S&P AIM unavailable / 5.36% |
LoseAIM / S&P AIM unavailable / 2.99% |
| 2019-Q30/3 |
LoseAIM / S&P -82.69% / 1.70% |
LoseAIM / S&P AIM unavailable / 5.02% |
LoseAIM / S&P AIM unavailable / 0.21% |
| 2019-Q20/3 |
LoseAIM / S&P -37.64% / 4.30% |
LoseAIM / S&P AIM unavailable / 6.64% |
LoseAIM / S&P AIM unavailable / 8.65% |
| 2019-Q10/3 |
LoseAIM / S&P -11.11% / 13.65% |
LoseAIM / S&P AIM unavailable / 8.12% |
LoseAIM / S&P AIM unavailable / 14.29% |
| 2018-Q40/3 |
LoseAIM / S&P -21.74% / -13.52% |
LoseAIM / S&P -16.02% / 9.05% |
LoseAIM / S&P AIM unavailable / 18.23% |
| 2018-Q30/3 |
LoseAIM / S&P -28.13% / 7.71% |
LoseAIM / S&P -56.08% / 10.21% |
LoseAIM / S&P AIM unavailable / 19.06% |
| 2018-Q20/3 |
LoseAIM / S&P -20.00% / 3.43% |
LoseAIM / S&P -31.64% / 9.03% |
LoseAIM / S&P AIM unavailable / 14.46% |
| 2018-Q12/3 |
WinAIM / S&P 14.29% / -0.76% |
WinAIM / S&P 198.54% / 7.68% |
LoseAIM / S&P AIM unavailable / 12.46% |
| 2017-Q42/3 |
WinAIM / S&P 9.37% / 6.64% |
WinAIM / S&P 375.00% / 7.03% |
LoseAIM / S&P AIM unavailable / 13.82% |
| 2017-Q31/3 |
LoseAIM / S&P -36.00% / 4.48% |
WinAIM / S&P 291.26% / 5.68% |
LoseAIM / S&P AIM unavailable / 17.57% |
| 2017-Q21/3 |
LoseAIM / S&P -9.09% / 3.09% |
WinAIM / S&P 222.12% / 4.83% |
LoseAIM / S&P AIM unavailable / 17.74% |
| 2017-Q10/3 |
LoseAIM / S&P -20.29% / 6.07% |
LoseAIM / S&P 0.74% / 3.67% |
LoseAIM / S&P AIM unavailable / 13.32% |
| 2016-Q40/3 |
LoseAIM / S&P -45.24% / 3.82% |
LoseAIM / S&P -30.83% / 2.09% |
LoseAIM / S&P AIM unavailable / 7.05% |
| 2016-Q30/3 |
LoseAIM / S&P -12.50% / 3.85% |
LoseAIM / S&P -29.45% / 0.20% |
LoseAIM / S&P AIM unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AIM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.48% | 20.78% |
| Annualized return | -89.48% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AIM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.88% | 83.14% |
| Annualized return | -73.78% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AIM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -63.46% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |